logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux

Merck KGaA (MKGAY.PK) announced that the National Institute for Health and Care Excellence or NICE for England has issued a positive Final Appraisal Determination or FAD recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with platinum-based chemotherapy as a first-line therapy for the treatment of patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity.

NICE's decision confirmed the positive benefit Erbitux can have on the survival of patients in this setting. Erbitux is already established and reimbursed as an effective therapy for different stages of SCCHN across many countries worldwide.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While Democrats have largely been critical of the Republican tax reform plan, President Donald Trump has claimed the proposal has some bipartisan support. Trump suggested to reporters ahead of a meeting with members of the Senate Finance Committee on Wednesday that "people on both sides" support the tax reform plan. Healthcare is very expensive in the U.S., in fact among the most expensive in the world by most measures. Health care facilities are largely owned and operated by businesses in the private sector. Most Americans have access to health care, though costs and services vary from state to state. However,... Electronic Arts Inc. said it is shutting down its Visceral Games Studio and making major changes to its upcoming Star Wars project currently being developed by the studio. Visceral Games is best known for creating the "Dead Space" series.
comments powered by Disqus
Follow RTT